A number of promising agents that target the interactions of the MDS/AML clone with MSPCs are currently in various phases of clinical testing (e.g., hypomethylating agents, lenalidomide, TGFβ-superfamily ligand traps, and adoptive MSPC transfer–based approaches). Here, TGFB1 is linked to acute myeloid leukemia.